研究不同时间注射甘精胰岛素治疗1型糖尿病的临床疗效

目的:分析使用甘精胰岛素治疗1型糖尿病时不同注射时间对疾病有效性的研究.方法:研究样本为我院2016年7月-2019年7月间收入治疗的84例1型糖尿病患者,根据就诊顺序差异性将纳入病例均分为2组,全部患者均接受甘精胰岛素注射治疗,对比组(n=42)患者在睡前注射,观察组(n=42)在清晨注射,对比两组患者最终治疗效果....     

青岛地区儿童青少年1型糖尿病持续皮下胰岛素输注与每日多次注射胰岛素治疗的成本效果比较

目的 比较持续皮下胰岛素输注(continuous subcutaneous insulin infusion,CSII)与每日多次注射(multipledaily injection,MDI)胰岛素治疗0～18岁儿童青少年1型糖尿病(type 1 diabetes mellitus,T1DM)的卫生经济学获益.方法 ...     

营养干预结合注射胰岛素治疗儿童糖尿病

0 引言 儿童糖尿病大多数是1型糖尿病(IDDM)[1],因遗传基因、免疫因素、环境因素共同参与而患病.2006年1月至2008年11月,我院内分泌科收治IDDM病儿43例,经临床应用胰岛素泵持续皮下注射胰岛素(CSII)结合营养治疗,取得良好的效果,现报道如下.     

胰岛素不同注射方式治疗儿童糖尿病的疗效及护理风险分析

目的：讨论持续胰岛素皮下注射和多次胰岛素皮下注射方法在治疗儿童糖尿病的疗效,并分析不同注射方法的护理风险。方法：将90例儿童糖尿病患者按随机数字表法分为观察组和对照组,每组各45例。观察组采用持续胰岛素皮下注射,对照组采用多次胰岛素皮下注射。比较两组在治疗前后的空腹血糖和餐后2 h血糖,同时记录血糖达标时间和胰岛素使用量,并观察治疗期间两组发生的护理风险,以评价不同注射方法治疗糖尿病的效果和风险。结果：观察组治疗后的空腹血糖、餐后2 h血糖、血糖达标时间、胰岛素使用量分别为（5.37±0.49）mmol/L、（7.67±0.86）mmol/L、（5.29±1.12）d和（37.21±2.09）U/d,与对照组比较差异均有统计学意义。观察组未发生针刺伤、剂量错误、注射用具错误和漏液情况,分别有3例和2例出现低血糖和穿刺点感染;对照组针刺伤7例、剂量错误4例、注射用具错误7例、漏液9例、低血糖10例和穿刺点感染11例,两组在护理风险方面比较差异有统计学意义（P〈0.05）。结论：持续皮下注射相比于多次皮下注射,可以更有效的降低血糖,缩短达标时间、减少胰岛素使用量,并避免护理风险,是治疗糖尿病有效的注射方法。     

胰岛素在治疗儿童1型糖尿病患者中的作用

目的:探讨胰岛素治疗儿童糖尿病的疗效.方法:32例儿童糖尿病住院患者随机分为胰岛素泵治疗组(16例)和常规皮下注射组(16例),进行胰岛素治疗及护理,比较两种治疗方法血糖变化、糖化血红蛋白变化、胰岛素用量及低血糖发生次数.结果:经胰岛素治疗和合理进行饮食运动治疗,两组患者血糖和糖化血红蛋白均明显下降.结论:持续皮下胰岛素输注(csii)能更好地控制血糖,降低低血糖的发生率.     

初诊2型糖尿病合并脑卒中患者应用不同胰岛素治疗方案的效果

目的探讨胰岛素泵输注胰岛素和多次胰岛素皮下注射对初诊2型糖尿病合并脑卒中患者的疗效。方法选取2017年6月至2018年4月本院收治的2型糖尿病患者40例,随机分为观察组和对照组,每组20例。观察组采取胰岛素泵输注胰岛素,对照组采取多次胰岛素皮下注射。比较两组患者的血糖控制情况、胰岛素用量、美国国立卫生研究院脑卒中量表(NIHSS)评分、胰岛素分泌指数及胰岛素抵抗指数。结果观察组患者血糖达标时间为(3.43±0.68)d,明显短于对照组的(6.71±0.95)d,胰岛素用量也明显少于对照组,差异均有统计学意义(均P0.05);治疗14 d后两组患者NIHSS评分均明显低于治疗前,其中观察组NIHSS评分明显低于对照组,差异均有统计学意义(均P0.05)。治疗14 d后,两组患者胰岛素分泌指数明显高于治疗前,差异均有统计学意义(均P0.05);但空腹胰岛素与治疗前相比差异均无统计学意义(均P0.05)。治疗14 d后,两组患者2 h C肽明显高于治疗前,胰岛素抵抗指数明显低于治疗前,差异均有统计学意义(均P0.05);但空腹C肽与治疗前相比差异均无统计学意义(均P0.05)。结论胰岛素泵输注胰岛素能够有效缩短初诊2型糖尿病合并脑卒中患者血糖达标时间,减少胰岛素用量,有助于改善神经功能缺损症状。     

地特胰岛素联合门冬胰岛素治疗儿童1型糖尿病的疗效观察

目的探讨地特胰岛素联合门冬胰岛素治疗儿童1型糖尿病(T1DM)的临床疗效。方法选取贵阳市某医院2013年1月—2017年3月收治的30例T1DM患儿为研究对象。采用随机数字表法将患儿分为研究组与对照组,每组15例。研究组患儿采用地特胰岛素联合门冬胰岛素治疗,对照组患儿采用门冬胰岛素联合中性鱼精蛋白锌胰岛素治疗。比较2组患儿治疗前及治疗6个月时糖化血红蛋白(HbA1c)、空腹血糖水平及体质量指数(BMI)。比较2组患儿低血糖发生情况。结果治疗前,2组患儿HbA1c、空腹血糖水平及BMI比较,差异无统计学意义(P0.05)。治疗6个月时,2组患儿HbA1c、空腹血糖水平低于治疗前,差异有统计学意义(P0.05)。治疗6个月时,对照组患儿BMI高于治疗前,差异有统计学意义(P0.05);研究组患儿BMI无显著变化(P0.05);研究组患儿BMI低于对照组,差异有统计学意义(P0.05)。研究组患儿低血糖发生率为6.67%,低于对照组的66.7%,差异有统计学意义(χ2=11.627,P0.05)。结论地特胰岛素联合门冬胰岛素治疗儿童T1DM,可降低患儿发生低血糖及体质量增加的风险,临床效果显著,值得推广应用。     

指导糖尿病患者自行注射胰岛素治疗效果观察

指导糖尿病患者自行注射胰岛素治疗效果观察陈基纯胰岛素是治疗糖尿病（ＤＭ）的主要药物，由于常采用皮下注射或静脉滴注等给药方法或因为病人对疾病和药物应用缺乏认识，使一些病人在出院后不能规则用药或自行停药，因而容易使病情加重或发生并发症。可见，患者不会自行...     

儿童一型糖尿病的胰岛素治疗方式

小儿糖尿病为现代儿童的常见疾病,尤其以一型糖尿病较为多见,这严重威胁了儿童的身体健康.对此病例,本文主要结合临床经验,对该病例进行探讨和分析,主要配合胰岛素的治疗方法,从科学角度加以解析.希望能够为业界提供一些医学借鉴,同时丰富国内的相关资料.     

儿童1型糖尿病饮食治疗的临床效果观察

目的 分析饮食治疗在儿童1型糖尿病中的应用效果。方法 选取2016年1月1日至2017年12月31日入院治疗的129例1型糖尿病患儿作为研究对象,随机分为对照组和观察组,对照组患儿使用常规治疗方法,观察组患儿在常规治疗方法的基础上增加个体化的饮食治疗方案,对比分析治疗后空腹血糖、糖化血红蛋白和餐后2 h血糖情况。结果 观察组的空腹血糖、糖化血红蛋白和餐后2 h血糖均低于对照组,2组比较差异有统计学意义(P<0.05)。结论 饮食治疗对于儿童1型糖尿病有效。     

探讨胰岛素注射笔在糖尿病治疗中的应用效果

目的:对胰岛素注射笔在糖尿病治疗中的实际应用效果展开分析和探讨。方法:以我院2016年7月-2017年12月期间收治的44例糖尿病患者为对象,对其进行随机分组研究,其中,观察组患者22例,接受胰岛素注射笔治疗;对照组患者22例,接受常规治疗,对比患者临床疗效。结果:观察组患者注射治疗后的各项血糖水平评价指标显著优于对照组患者(P0.05);与此同时,观察组患者注射治疗期间发生的各项不良反应的比例明显低于对照组(P0.05)。结论:胰岛素注射笔在糖尿病治疗中的实际应用有着突出效果,是进一步提升患者治疗效果、保障患者治疗安全性的重要途径,推荐使用。     

儿童1型糖尿病

儿童糖尿病是由于胰岛素缺乏或作用不足所导致的慢性全身性疾病。临床以多尿、多饮、多食及消瘦为特征。发病年龄以10～15岁较多。发病率呈逐年上升的趋势。     

营养治疗应用于儿童1型糖尿病患儿的临床效果

目的 观察营养治疗应用于儿童1型糖尿病患儿的临床效果.方法 选择30例儿童1型糖尿病患儿,实施个体化营养治疗方案.结果 患儿摄入的能量、蛋白质、脂肪和碳水化合物基本符合中国居民膳食营养素参考摄入量标准;比较营养治疗前后,空腹血糖、餐后2h血糖差异有统计学意义(P＜0.01)；尿糖、尿酮全部转阴.结论 个体化的营养治疗有助于儿童1型糖尿病患儿控制血糖,促进生长发育,预防并发症的发生.     

持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析

Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program.     

持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析

Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program.     

持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析

Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program.     

持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析

Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program.     

持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析

Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program.     

持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析

Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program.